Ipamorelin
A selective growth hormone secretagogue that stimulates GH release from the pituitary without significantly affecting cortisol or prolactin.
Also known as: IPA, NNC 26-0161
Regulatory Status
Classification date: 2026-02-27
Reclassification to Category 1 announced but not yet formalized
Compounding: Not currently available for compounding
Evidence Summary
Key Studies
How It Works
Ipamorelin is a pentapeptide that binds to the ghrelin/GHS receptor (GHSR) on pituitary somatotrophs, triggering growth hormone release. Unlike older secretagogues (GHRP-6, GHRP-2), it is highly selective — it does not substantially increase cortisol, prolactin, or ACTH at therapeutic doses. It works synergistically with GHRH analogs like CJC-1295, amplifying GH pulses when administered together. This selectivity gives it a favorable side-effect profile.
Common Applications
Safety & Considerations
Well tolerated in clinical studies with a clean side-effect profile. Mild, transient effects may include headache, flushing, or dizziness. Does not cause the intense hunger associated with GHRP-6. Long-term safety data in humans is limited. Should be avoided in patients with active malignancies. Currently not legal for compounding in the US.
Related Research
Regulatory classifications can change rapidly. The information shown here was last verified on 2026-02-27. Always confirm current legal status with a licensed provider or the FDA before making treatment decisions.